|
|
|
|
|
|
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination With Cisplatin in Subjects With Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma
SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma
100 项与 RaND Bioscience, Inc. 相关的临床结果
0 项与 RaND Bioscience, Inc. 相关的专利(医药)
100 项与 RaND Bioscience, Inc. 相关的药物交易
100 项与 RaND Bioscience, Inc. 相关的转化医学